Compare
Alector, Inc. vs LENZ Therapeutics, Inc. vs Metagenomi Therapeutics, Inc. vs Pelthos Therapeutics Inc.
| Latest fiscal year | Alector, Inc. ALEC | LENZ Therapeutics, Inc. LENZ | Metagenomi Therapeutics, Inc. MGX | Pelthos Therapeutics Inc. PTHS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $21.05M | $19.09M | $25.21M | $16.80M |
| Revenue growth (YoY) | -79.1% | n/a | -51.8% | n/a |
| Gross margin | n/a | n/a | n/a | 76.3% (computed) |
| Operating margin | -741.3% | -477.5% | -380.9% | -193.1% |
| Net margin | -679.2% | -430.3% | -348.5% | -257.9% |
| Net income | -$142.93M | -$82.13M | -$87.87M | -$43.32M |
| EPS (Diluted) | -$1.39 | -$2.85 | -$2.36 | -$23.04 |
| Operating cash flow | -$184.03M | -$69.17M | -$88.89M | -$22.59M |
| Free cash flow | -$184.07M | -$70.00M | -$89.47M | -$22.69M |
| Cash & equivalents | $65.80M | $25.18M | $41.72M | $17.97M |
| Total assets | $293.24M | $305.88M | $221.10M | $130.40M |
| Total liabilities | $262.59M | $21.54M | $62.51M | $91.52M |
| Shareholders' equity | $30.65M | $284.34M | $158.60M | $38.88M |
| Return on year-end equity | -466.3% | -28.9% | -55.4% | -111.4% |
| Shares outstanding | 110.36M | 31.34M | 37.62M | 3.23M |
Revenue, most recent five fiscal years
| Fiscal year | Alector, Inc. | LENZ Therapeutics, Inc. | Metagenomi Therapeutics, Inc. | Pelthos Therapeutics Inc. |
|---|---|---|---|---|
| Latest | $21.05M Ended 2025-12-31 | $19.09M Ended 2025-12-31 | $25.21M Ended 2025-12-31 | $16.80M Ended 2025-12-31 |
| 1 year earlier | $100.56M Ended 2024-12-31 | $0 Ended 2024-12-31 | $52.30M Ended 2024-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | $97.06M Ended 2023-12-31 | n/a | $44.76M Ended 2023-12-31 | n/a |
| 3 years earlier | $133.62M Ended 2022-12-31 | n/a | n/a | n/a |
| 4 years earlier | $207.09M Ended 2021-12-31 | n/a | n/a | n/a |